SEC Form 4 · accession 0001209191-18-048025
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve E. Krognes
Officer — CFO and Treasurer
Period of report
Aug 20, 2018
Accepted (ET)
Aug 22, 2018 · 5:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 20, 2018 | A | 11,286 | A | — | — | Common Stock | 11,286 | 11,286 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- F250% of the restricted stock units shall vest on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through each such date.